Search

Search Constraints

You searched for: Author/Creator Deniz, Yamo

Search Results

11. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. (October 2022)

13. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma. Issue 1 (9th August 2022)

14. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Issue 7 (21st February 2021)

15. Improvement in patient‐reported "taste" and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials. Issue 9 (12th July 2022)

16. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Issue 1 (January 2022)

17. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps. Issue 7 (23rd January 2022)

18. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies. Issue 2 (28th January 2022)

19. S381 Esophageal Eosinophil Count Does Not Correlate With the Endoscopic Reference Score Remodeling Subscore in Placebo-Treated Eosinophilic Esophagitis Patients in the Phase 2 Proof-of-Concept and Phase 3 TREET Studies. (October 2021)

20. S420 The Histological Scoring System and Endoscopic Reference Score Are Complementary Assessments for Characterizing Fibrostenotic or Inflammatory Phenotypes in Patients with Eosinophilic Esophagitis. (October 2021)